Literature DB >> 20553989

Persistent detection of a novel MLL-SACM1L rearrangement in the absence of leukemia.

Takeshi Mori1, Noriyuki Nishimura, Daiichiro Hasegawa, Keiichiro Kawasaki, Yoshiyuki Kosaka, Kazuko Uchide, Tomoko Yanai, Akira Hayakawa, Yasuhiro Takeshima, Hisahide Nishio, Masafumi Matsuo.   

Abstract

Most chromosomal rearrangements including the mixed lineage leukemia (MLL) gene are manifested as leukemia and predict a poor prognosis. Although more than 50 MLL-rearrangement partners are characterized, MLL-related leukemogenesis remains to be understood. Here we report a case of a 3-year old boy bearing a novel MLL-rearrangement with the suppressor of actin mutations 1-like (SACM1L) gene in the absence of leukemia. Bone marrow cells harboring the MLL-SACM1L rearrangement appeared during chemotherapy for acute lymphoblastic leukemia with hyperdiploidy and were continuously detected over 7 years without clonal expansion. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20553989     DOI： 10.1016/j.leukres.2010.05.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  2 in total

1.  Changes in leukocyte gene expression profiles induced by antineoplastic chemotherapy.

Authors:  Rebeca González-Fernández; Manuel Morales; Julio Avila; Pablo Martín-Vasallo
Journal:  Oncol Lett       Date:  2012-04-03       Impact factor: 2.967

2.  The MLL recombinome of acute leukemias in 2017.

Authors:  C Meyer; T Burmeister; D Gröger; G Tsaur; L Fechina; A Renneville; R Sutton; N C Venn; M Emerenciano; M S Pombo-de-Oliveira; C Barbieri Blunck; B Almeida Lopes; J Zuna; J Trka; P Ballerini; H Lapillonne; M De Braekeleer; G Cazzaniga; L Corral Abascal; V H J van der Velden; E Delabesse; T S Park; S H Oh; M L M Silva; T Lund-Aho; V Juvonen; A S Moore; O Heidenreich; J Vormoor; E Zerkalenkova; Y Olshanskaya; C Bueno; P Menendez; A Teigler-Schlegel; U Zur Stadt; J Lentes; G Göhring; A Kustanovich; O Aleinikova; B W Schäfer; S Kubetzko; H O Madsen; B Gruhn; X Duarte; P Gameiro; E Lippert; A Bidet; J M Cayuela; E Clappier; C N Alonso; C M Zwaan; M M van den Heuvel-Eibrink; S Izraeli; L Trakhtenbrot; P Archer; J Hancock; A Möricke; J Alten; M Schrappe; M Stanulla; S Strehl; A Attarbaschi; M Dworzak; O A Haas; R Panzer-Grümayer; L Sedék; T Szczepański; A Caye; L Suarez; H Cavé; R Marschalek
Journal:  Leukemia       Date:  2017-07-13       Impact factor: 11.528
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.